John Libbey Eurotext

Eslicarbazepine for focal epilepsy and acute intermittent porphyria Volume 22, issue 3, June 2020

Tables

Authors
University of Montreal Hospital Center, Montreal, Quebec, Canada
* Correspondence: Dang K. Nguyen University of Montreal Health Center, 1000 Saint-Denis, Montreal, H2X 0C1, Canada

Porphyrias are rare genetic disorders which cause a deficiency in the enzymes involved in the biosynthesis of heme. The treatment of epilepsy in patients with acute intermittent porphyria can be difficult since many anticonvulsants can increase heme synthesis and trigger porphyric attacks. We report a patient with focal epilepsy successfully treated with eslicarbazepine without exacerbation of porphyria.